"PathXL's pioneering digital pathology solutions are highly versatile," notes Frost & Sullivan Senior Research Analyst Prasanna Vadhana Kannan. "They allow pathologists to adopt digital pathology for inter-laboratory collaboration and then expand the utility of these systems to diverse digital pathology services such as remote consultations, quality assurance programmes, proficiency testing and training, quantitative imaging and pattern recognition."

The proprietary PathXL TMA (tissue microarray) software represents a biomarker discovery tool that can facilitate the identification and scoring of tissue biomarkers in high throughput tissue microarray format. As a preclinical biomarker discovery research-enabling tool, the PathXL TMA software is entirely web-enabled and allows researchers to share TMA slides instantly across large geographical distances, score the slides simultaneously, and integrate dispersed research laboratories.

PathXL's software operates with a large spectrum of image formats, spanning different whole slide scanning instruments. PathXL puts workflow at the heart of its products, bringing new capabilities to customers who are investing in hardware to scan tissue pathology.

"The company's products are designed to integrate with existing IT systems within research and clinical laboratories enabling PathXL to develop solutions for a wide application range," adds Prasanna Vadhana Kannan. "PathXL's digital pathology educational and management solutions underpin a wide range of applications including education and training in pathology, digital slide archiving, cloud-based digital pathology, biobanking, biomarker discovery and data management, and web-based image analysis for tissue research."

PathXL Ltd. has been actively partnering with cancer research programmes in Northern Ireland, providing the backbone tissue management software for these initiatives. The company's web-based solutions have allowed Northern Ireland's research community to share their microscope samples globally with other researchers via the web, thereby improving the identification of disease markers and development of newer cancer therapies.

PathXL has also worked closely with medical and scientific staff at the Northern Ireland Biobank to develop a new comprehensive biobank workflow software platform. This new product – PathXL Biobank- meets the increasing needs of modern biobanks, supporting researchers that need access to human tissues for biomarker discovery.

Digital Pathology Workflow, a configurable solution that manages and streamlines digital pathology workflow in hospitals and pathology laboratories, is PathXL's latest product offering. On the corporate front, PathXL's strategic partnership with DigiPath Inc. in the United States aims to increase user adoption of the suite of PathXL digital pathology educational products.

"PathXL's full range of national and international research collaborations emphasize the uniqueness behind the company's digital pathology services that offer exceptional speed, flexibility, and objectivity needed for biomarker assessment in particular," concludes Prasanna Vadhana Kannan. "Frost & Sullivan feels that PathXL's integrated digital pathology solutions are poised for easy transition and high recognition."

The Enabling Technology Award is presented to the company that has excelled in enabling the creation of new products and applications and/or has enhanced current products. Potential for market acceptance and breadth of access to technology are other criterion in which the company is seen to have excelled.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.